Search

Author/Creator Scaramozza, Matthew

1. Chronic lesion activity and disability progression in secondary progressive multiple sclerosis. Issue 1 (8th June 2022)

Authors:
Beynon, Vanessa; George, Ilena C; Elliott, Colm; Arnold, Douglas L; Ke, Jun; Chen, Huaihou; Zhu, Li; Ke, Chunlei; Giovannoni, Gavin; Scaramozza, Matthew; Campbell, Nolan; Bradley, Daniel P; Franchimont, Nathalie; Gafson, Arie; Belachew, Shibeshih
Journal:
BMJ neurology open
Issue:
Volume 4:Issue 1(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells. Issue 6 (14th June 2021)

Authors:
Bame, Eris; Tang, Hao; Burns, Jeremy C; Arefayene, Million; Michelsen, Klaus; Ma, Bin; Marx, Isaac; Prince, Robin; Roach, Allie M; Poreci, Urjana; Donaldson, Douglas; Cullen, Patrick; Casey, Fergal; Zhu, Jing; Carlile, Thomas M; Sangurdekar, Dipen; Zhang, Baohong; Trapa, Patrick; Santoro, Joseph;...
Journal:
Clinical & translational immunology
Issue:
Volume 10:Issue 6(2021)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study. Issue 2 (8th December 2020)

Authors:
Singh, Ravi Shankar P.; Pradhan, Vivek; Roberts, Erika S.; Scaramozza, Matthew; Kieras, Elizabeth; Gale, Jeremy D.; Peeva, Elena; Vincent, Michael S.; Banerjee, Anindita; Fensome, Andrew; Dowty, Martin E.; Winkle, Peter; Tehlirian, Christopher
Journal:
Clinical and translational science
Issue:
Volume 14:Issue 2(2021)
Page Start:
671
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. (March 2021)

Authors:
Tehlirian, Christopher; Peeva, Elena; Kieras, Elizabeth; Scaramozza, Matthew; Roberts, Erika S; Singh, Ravi Shankar P; Pradhan, Vivek; Banerjee, Anindita; Garcet, Sandra; Xi, Li; Gale, Jeremy D; Vincent, Michael S; Krueger, James
Journal:
Lancet
Issue:
Volume 3:Number 3(2021)
Page Start:
e204
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis. (21st December 2017)

Authors:
Banfield, Christopher; Scaramozza, Matthew; Zhang, Weidong; Kieras, Elizabeth; Page, Karen M.; Fensome, Andrew; Vincent, Michael; Dowty, Martin E.; Goteti, Kosalaram; Winkle, Peter J.; Peeva, Elena
Journal:
Journal of clinical pharmacology
Issue:
Volume 58:Number 4(2018)
Page Start:
434
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗